New tobacco-based flu vaccine offers promising alternative to egg-based versions, says GlobalData analyst

11-Mar-2016

This virus-like particle (VLP) influenza vaccine is being developed by Japan's Mitsubishi Tanabe Pharma

A new tobacco-based virus-like particle (VLP) influenza vaccine being developed by Japan's Mitsubishi Tanabe Pharma could potentially rival traditional chicken egg-based vaccines, according to an analyst with research and consulting firm GlobalData.

The vaccine, currently in Phase III studies, is expected to be launched in the US for the 2018–19 flu season.

The technology, originally developed by Canadian firm Medicago, which was acquired by Mitsubishi Tanabe for US$357m in 2013, involves implanting influenza genetic material into tobacco leaves. The technology enables vaccine production in four weeks, six times faster than egg-based methods.

Achilleas Livieratos, GlobalData’s Analyst covering Infectious Diseases, says there are a number of limitations with the use of egg-based vaccines, leaving a substantial need for alternatives.

'As well as taking six months to work, during which time minor genetic mutations can decrease vaccine efficacy, individuals with egg allergies cannot safely receive vaccines, leaving them vulnerable to infection,' he says.

Mitsubishi Tanabe’s pipeline tobacco product is one of a number of VLP influenza vaccines set to take over from the traditional kind

'A number of vaccine giants including Sanofi, GlaxoSmithKline and MedImmune/AstraZeneca are also developing their vaccine portfolios. However, their current egg-based, quadrivalent, inactivated (split virus) seasonal influenza vaccines lack the manufacturing efficiency of tobacco plant-derived vaccines that can also generate virus-like particles (VLPs).'

Livieratos adds that Novavax has already advanced its insect cell-based VLP seasonal influenza vaccine candidate into Phase III of clinical development, ahead of Mitsubishi Tanabe. But he says important differences exist between plant-based and conventional cell culture-based production methods, as the former boasts reduced infrastructure cost and half the production time compared with the latter.

Livieratos continues: 'Mitsubishi Tanabe’s pipeline tobacco product is one of a number of VLP influenza vaccines set to take over from the traditional kind, as they represent an exciting emerging vaccine class that can generate effective and longer-lasting protection while also being amenable to a diverse array of production methods.

Sign up for your free email newsletter

'Mitsubishi Tanabe will need to demonstrate strong safety data and yearly production consistency of its tobacco-based vaccine. If the company’s product, or one like it, is approved, GlobalData expects a novel vaccine that boasts a rapid, plant-based manufacturing process to have a significant impact on the seasonal influenza vaccine landscape.'

Companies

Featured Companies

Related Content

Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment
Eli Lilly’s acquisition of Loxo Oncology will result in quick return of investment
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
BMS' acquisition of Celgene could position the company amongst top five most profitable pharma giants
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
Drug pricing and reimbursement concerns will remain the leading impediment to industry growth in 2019
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
R&D returns fall to lowest level in 9 years, says Deloitte and GlobalData
Drug development in neuroimmunology to witness strong growth in the 8MM
Drug development in neuroimmunology to witness strong growth in the 8MM
Immuno-oncology drug development and personalised medicine will continue to reshape the pharma industry in 2019
Immuno-oncology drug development and personalised medicine will continue to reshape the pharma industry in 2019
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
GSK and Pfizer deal shows shift in strategy shift to create the leader in over-the-counter products
Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead
Bayer receives European approval for haemophilia drug Jivi ... but has stiff competition ahead
Second failure of AstraZeneca’s Imfinzi + tremelimumab combination significant setback says GlobalData
Second failure of AstraZeneca’s Imfinzi + tremelimumab combination significant setback says GlobalData
Commercial opportunities for emerging infectious diseases vaccine developers
Commercial opportunities for emerging infectious diseases vaccine developers
Non-small cell lung cancer market projected to be worth $14.6 billion by 2024
Non-small cell lung cancer market projected to be worth $14.6 billion by 2024
Sandoz abandons US development of Rixathon
Sandoz abandons US development of Rixathon
Global glioblastoma market set to reach $1.4bn by 2027
Global glioblastoma market set to reach $1.4bn by 2027
Pancreatic cancer treatment heads in promising direction, says GlobalData
Pancreatic cancer treatment heads in promising direction, says GlobalData
Further development of CAR-T cell therapy requires industry input
Further development of CAR-T cell therapy requires industry input
Brexit could force UK to relinquish control of pharma regulations
Brexit could force UK to relinquish control of pharma regulations